Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial

I Schwartz, ME Boesen, G Cerchiaro… - … Open Access Journal, 2021 - cmajopen.ca
Background: Identification of therapies to prevent severe COVID-19 remains a priority. We
sought to determine whether hydroxychloroquine treatment for outpatients with SARS-CoV-2 …

Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial

WH Self, MW Semler, LM Leither, JD Casey, DC Angus… - Jama, 2020 - jamanetwork.com
Importance Data on the efficacy of hydroxychloroquine for the treatment of coronavirus
disease 2019 (COVID-19) are needed. Objective To determine whether hydroxychloroquine …

[HTML][HTML] Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE–Coalition V): A double-blind, multicentre, randomised …

Á Avezum, GBF Oliveira, H Oliveira… - The Lancet Regional …, 2022 - thelancet.com
Summary Background Previous Randomised controlled trials (RCT) evaluating chloroquine
and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …

[HTML][HTML] Effect of hydroxychloroquine in hospitalized patients with Covid-19

RECOVERY Collaborative Group - New England Journal of …, 2020 - Mass Medical Soc
Background Hydroxychloroquine and chloroquine have been proposed as treatments for
coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from …

Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19

SM Lofgren, MR Nicol, AS Bangdiwala… - Open forum …, 2020 - academic.oup.com
Background Use of hydroxychloroquine in hospitalized patients with coronavirus disease
2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns …

Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital

O Paccoud, F Tubach, A Baptiste… - Clinical Infectious …, 2021 - academic.oup.com
Background Data from nonrandomized studies have suggested that hydroxychloroquine
could be an effective therapeutic agent against coronavirus disease 2019 (COVID-19) …

Hydroxychloroquine for treatment of non‐hospitalized adults with COVID‐19: A meta‐analysis of individual participant data of randomized trials

O Mitjà, G Reis, DR Boulware… - Clinical and …, 2023 - Wiley Online Library
Hydroxychloroquine (HCQ) was initially promoted as an oral therapy for early treatment of
coronavirus disease 2019 (COVID‐19). Conventional meta‐analyses cannot fully address …

[HTML][HTML] Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study

M Kalligeros, F Shehadeh, E Atalla, EK Mylona… - Journal of Global …, 2020 - Elsevier
Aim To assess the efficacy and safety of hydroxychloroquine with or without azithromycin) in
hospitalized adult patients with COVID-19. Methods We utilized a hospital based …

[HTML][HTML] Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study

A Ip, J Ahn, Y Zhou, AH Goy, E Hansen… - BMC infectious …, 2021 - Springer
Background Hydroxychloroquine has not been associated with improved survival among
hospitalized COVID-19 patients in the majority of observational studies and similarly was not …

[HTML][HTML] Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: a randomized controlled trial

C Hernandez-Cardenas, I Thirion-Romero… - PLoS …, 2021 - journals.plos.org
Introduction The novel coronavirus pandemic (COVID–19) represents a major public health
problem and it is key to find a treatment that reduces mortality. Our objective was to estimate …